Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome

American Journal of Cardiology

Volumn 108, Issue 6, 2011, Pages 760-765

  Cuisset, Thomas ^a,b   Quilici, Jacques ^a   Cohen, William ^a,b   Fourcade, Laurent ^c   Saut, Noémie ^a,b   Pankert, Mathieu ^a   Gaborit, Bénédicte ^a,b   Carrieri, Patrizia ^d,e   Morange, Pierre Emmanuel ^a,b   Bonnet, Jean Louis ^a   Alessi, Marie Christine ^a,b  

^a TIMONE HOSPITAL   (France)

^b INSERM   (France)

^c LAVERAN MILITARY TEACHING HOSPITAL   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ALLELE; ARTICLE; CORONARY STENT; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NON ST ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY INDEX; PRIORITY JOURNAL; RATING SCALE;

ACUTE CORONARY SYNDROME; ALLELES; ANALYSIS OF VARIANCE; ARYL HYDROCARBON HYDROXYLASES; CHI-SQUARE DISTRIBUTION; DRUG RESISTANCE; ENDPOINT DETERMINATION; FEMALE; FLOW CYTOMETRY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STATISTICS, NONPARAMETRIC; STENTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 80052285369     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2011.05.045     Document Type: Article

References (33)

1. M.E. Bertrand, H.J. Rupprecht, P. Urban, A.H. Gershlick, and F.T. Investigators Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS) Circulation 102 2000 624 629 (Pubitemid 30640661)
2. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, and K.K. Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502 (Pubitemid 32758501)
3. S.R. Mehta, S. Yusuf, R.J. Peters, M.E. Bertrand, B.S. Lewis, M.K. Natarajan, K. Malmberg, H. Rupprecht, F. Zhao, S. Chrolavicius, I. Copland, K.A. Fox Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533 (Pubitemid 32772726)
4. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, T.A. Bass, and M.A. Costa Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516 (Pubitemid 46517957)
5. S. Matetzky, B. Shenkman, V. Guetta, M. Shechter, R. Bienart, I. Goldenberg, I. Novikov, H. Pres, N. Savion, D. Varon, and H. Hod Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
6. T. Cuisset, C. Frere, J. Quilici, F. Barbou, P.E. Morange, T. Hovasse, J.L. Bonnet, and M.C. Alessi High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome J Thromb Haemost 4 2006 542 549
7. T. Geisler, H. Langer, M. Wydymus, K. Göhring, C. Zrn, B. Bigalke, K. Stellos, A.E. May, and M. Gawaz Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation Eur Heart J 27 2006 2420 2425 (Pubitemid 44522148)
8. W. Hochholzer, D. Trenk, H.P. Bestehorn, B. Fischer, C.M. Valina, M. Ferenc, M. Gick, A. Caputo, H.J. Bttner, and F.J. Neumann Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement J Am Coll Cardiol 48 2006 1742 1750 (Pubitemid 44648629)
9. P. Buonamici, R. Marcucci, A. Migliorini, G.F. Gensini, A. Santini, R. Paniccia, G. Moschi, A.M. Gori, R. Abbate, and D. Antoniucci Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis J Am Coll Cardiol 49 2007 2312 2317 (Pubitemid 46891710)
10. T. Cuisset, G. Cayla, C. Frere, J. Quilici, R. Poyet, B. Gaborit, L. Bali, P.E. Morange, M.C. Alessi, and J.L. Bonnet Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome Shifting from antiplatelet resistance to bleeding risk assessment? Eurointervention 5 2009 325 329
11. D. Sibbing, S. Schulz, S. Braun, T. Morath, J. Stegherr, J. Mehilli, A. Schömig, N. von Beckerath, and A. Kastrati Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement J Thromb Haemost 8 2010 250 256
12. P. Savi, J.M. Herbert, A.M. Pflieger, F. Dol, D. Delebassee, J. Combalbert, G. Defreyn, and J.P. Maffrand Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel Biochem Pharmacol 44 1992 527 532
13. P. Savi, J. Combalbert, C. Gaich, M.C. Rouchon, J.P. Maffrand, Y. Berger, and J.M. Herbert The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A Thromb Haemost 72 1994 313 317 (Pubitemid 24251300)
14. G. Hollopeter, H.M. Jantzen, D. Vincent, G. Li, L. England, V. Ramakrishnan, R.B. Yang, P. Nurden, A. Nurden, D. Julius, and P.B. Conley Identification of the platelet ADP receptor targeted by antithrombotic drugs Nature 409 2001 202 207 (Pubitemid 32144286)
15. T. Cuisset, P.E. Morange, J. Quilici, L. Camoin-Jau, N. Saut, D. Faille, M. Lambert, I. Juhan-Vague, J.L. Bonnet, and M.C. Alessi Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome Am J Cardiol 101 2008 1088 1093
16. J.P. Collet, J.S. Hulot, A. Pena, E. Villard, J.B. Esteve, J. Silvain, L. Payot, D. Brugier, G. Cayla, F. Beygui, G. Bensimon, C. Funck-Brentano, and G. Montalescot Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
17. J.S. Hulot, J.P. Collet, J. Silvain, A. Pena, A. Bellemain-Appaix, O. Barthélémy, G. Cayla, F. Beygui, and G. Montalescot Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19 (*)2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis J Am Coll Cardiol 56 2010 134 143
18. J.P. Collet, G. Cayla, T. Cuisset, S. Elhadad, G. Rangé, E. Vicaut, and G. Montalescot Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the Assessment With a Double Randomization of (1) a Fixed Dose Versus a Monitoring-Guided Dose of Aspirin and Clopidogrel After DES Implantation, and (2) Treatment Interruption Versus Continuation, 1 Year After Stenting (ARCTIC) study Am Heart J 161 2011 5 12
19. G. Montalescot, G. Sideris, C. Meuleman, C. Bal-dit-Sollier, N. Lellouche, P.G. Steg, M. Slama, O. Milleron, J.P. Collet, P. Henry, F. Beygui, L. Drouet ALBION Trial Investigators A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial J Am Coll Cardiol 48 2006 931 938 (Pubitemid 44292463)
20. T. Cuisset, C. Frere, J. Quilici, P.E. Morange, L. Nait-Saidi, J. Carvajal, A. Lehmann, M. Lambert, J.L. Bonnet, and M.C. Alessi Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting J Am Coll Cardiol 48 2006 1339 1345 (Pubitemid 44436814)
21. N. von Beckerath, A. Kastrati, A. Wieczorek, G. Pogatsa-Murray, D. Sibbing, I. Graf, and A. Schömig A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days Eur Heart J 28 2007 1814 1819 (Pubitemid 47236637)
22. S.R. Mehta, J.P. Bassand, S. Chrolavicius, R. Diaz, J.W. Eikelboom, K.A. Fox, C.B. Granger, S. Jolly, C.D. Joyner, H.J. Rupprecht, P. Widimsky, R. Afzal, J. Pogue, S. Yusuf CURRENT-OASIS 7 Investigators Dose comparisons of clopidogrel and aspirin in acute coronary syndromes N Engl J Med 363 2010 930 942
23. U.R. Schwarz, J. Geiger, U. Walter, and M. Eigenthaler Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects Thromb Haemost 82 1999 1145 1152 (Pubitemid 29419734)
24. L. Bonello, U.S. Tantry, R. Marcucci, R. Blindt, D.J. Angiolillo, R. Becker, D.L. Bhatt, M. Cattaneo, J.P. Collet, T. Cuisset, C. Gachet, G. Montalescot, L.K. Jennings, D. Kereiakes, D. Sibbing, D. Trenk, J.W. Van Werkum, F. Paganelli, M.J. Price, R. Waksman, P.A. Gurbel Working Group on High On-Treatment Platelet Reactivity Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
25. L. Bonello, L. Camoin-Jau, S. Arques, C. Boyer, D. Panagides, O. Wittenberg, M.C. Simeoni, P. Barragan, F. Dignat-George, and F. Paganelli Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol 51 2008 1404 1411 (Pubitemid 351447314)
26. T. Cuisset, C. Frere, J. Quilici, P.E. Morange, J.P. Mouret, L. Bali, P.J. Moro, M. Lambert, M.C. Alessi, and J.L. Bonnet Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopi dogrel non-responders: a prospective, randomized study JACC Cardiovasc Interv 1 2008 649 653
27. M. Valgimigli, G. Campo, N. de Cesare, E. Meliga, P. Vranckx, A. Furgieri, D.J. Angiolillo, M. Sabat, M. Hamon, A. Repetto, S. Colangelo, S. Brugaletta, G. Parrinello, G. Percoco, R. Ferrari Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T./2R.) Investigators Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study Circulation 119 2009 3215 3222
28. M.J. Price, P.B. Berger, P.S. Teirstein, J.F. Tanguay, D.J. Angiolillo, D. Spriggs, S. Puri, M. Robbins, K.N. Garratt, O.F. Bertrand, M.E. Stillablower, J.R. Aragon, D.E. Kandzari, C.T. Stinis, M.S. Lee, S.V. Manoukian, C.P. Cannon, N.J. Schork, E.J. Topol GRAVITAS Investigators Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
29. S.D. Wiviott, D. Trenk, A.L. Frelinger, M. O'Donoghue, F.J. Neumann, A.D. Michelson, D.J. Angiolillo, H. Hod, G. Montalescot, D.L. Miller, J.A. Jakubowski, R. Cairns, S.A. Murphy, C.H. McCabe, E.M. Antman, E. Braunwald PRINCIPLE-TIMI 44 Investigators Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial Circulation 116 2007 2923 2932 (Pubitemid 350291199)
30. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, S. Gottlieb, F.J. Neumann, D. Ardissino, S. De Servi, S.A. Murphy, J. Riesmeyer, G. Weerakkody, C.M. Gibson, E.M. Antman TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
31. L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, C. Held, J. Horrow, S. Husted, S. James, H. Katus, K.W. Mahaffey, B.M. Scirica, A. Skene, P.G. Steg, R.F. Storey, R.A. Harrington, A. Freij, M. Thorsén PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 36 2009 1045 1057
32. L. Bonello, S. Armero, O. Ait Mokhtar, J. Mancini, P. Aldebert, N. Saut, N. Bonello, P. Barragan, S. Arques, M.P. Giacomoni, C. Bonello-Burignat, M.N. Bartholomei, F. Dignat-George, L. Camoin-Jau, and F. Paganelli Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19 (*)2 loss of function polymorphism J Am Coll Cardiol 56 2010 1630 1636
33. M.J. Price, P.B. Berger, P.S. Teirstein, J.F. Tanguay, D.J. Angiolillo, D. Spriggs, S. Puri, M. Robbins, K.N. Garratt, O.F. Bertrand, M.E. Stillablower, J.R. Aragon, D.E. Kandzari, C.T. Stinis, M.S. Lee, S.V. Manoukian, C.P. Cannon, N.J. Schork, E.J. Topol GRAVITAS Investigators Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105